0.6600 USD
-0.0300
4.35%
At close Jun 13, 4:00 PM EDT
Pre-market
0.6600
+0.0000
0.00%
1 day
-4.35%
5 days
-8.46%
1 month
-49.23%
3 months
-75.65%
6 months
-89.78%
Year to date
-87.50%
1 year
-89.46%
5 years
-99.33%
10 years
-99.33%
 

About: Movano Inc is developing a platform to deliver purpose-driven healthcare solutions to bring medical-grade, high-quality data to the forefront of consumer health devices. its initial commercial product in development is the Evie Ring, a wearable designed specifically for women. The Evie Ring combines health and wellness metrics to give a full picture of one's health, which includes resting heart rate, heart rate variability (HRV), blood oxygen saturation (SpO2), respiration rate, skin temperature variability, period and ovulation tracking, menstrual symptom tracking, activity profile, including steps, active minutes and calories burned, sleep stages and duration, and mood tracking.

Employees: 32

0
Funds holding %
of 7,296 funds
Analysts bullish %

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

133% more repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 3

13% more funds holding

Funds holding: 16 [Q4 2024] → 18 (+2) [Q1 2025]

2.19% more ownership

Funds ownership: 17.65% [Q4 2024] → 19.84% (+2.19%) [Q1 2025]

62% less capital invested

Capital invested by funds: $6.37M [Q4 2024] → $2.41M (-$3.97M) [Q1 2025]

Research analyst outlook

We haven’t received any recent analyst ratings for MOVE.

Financial journalist opinion

Neutral
PRNewsWire
3 weeks ago
Movano Health Receives Notification of Deficiency from Nasdaq Related to Delayed Filing of Quarterly Report on Form 10-Q
PLEASANTON, Calif. , May 23, 2025 /PRNewswire/ -- Movano Health (Nasdaq: MOVE )(the "Company") announced today that it received a notice (the "Notice") from the Listing Qualifications Department of the Nasdaq Stock Market ("Nasdaq") indicating that because the Company had not yet filed its Form 10-Q for the quarterly period ended March 31, 2025 (the "Form 10-Q"), the Company was not in compliance with Nasdaq Listing Rule 5250(c)(1) (the "Listing Rule") requiring Nasdaq-listed companies to timely file all periodic financial reports with the Securities and Exchange Commission (the "SEC").
Movano Health Receives Notification of Deficiency from Nasdaq Related to Delayed Filing of Quarterly Report on Form 10-Q
Neutral
PRNewsWire
1 month ago
Movano Health's Board of Directors Initiates Process to Maximize Shareholder Value
PLEASANTON, Calif. , May 16, 2025 /PRNewswire/ -- Movano Health (Nasdaq: MOVE), a pioneer in health technology, announced today that its Board of Directors has initiated a process to explore strategic alternatives, including a sale, merger or similar transaction involving the Company, to maximize shareholder value.
Movano Health's Board of Directors Initiates Process to Maximize Shareholder Value
Neutral
PRNewsWire
1 month ago
Movano Health's Proprietary Cuffless Blood Pressure Device Once Again Achieves Accuracy Commensurate with the FDA's Requirements
Leveraging the Company's System-on-a-Chip (SoC), the clinical study results are another significant step forward in commercializing a cuffless, radio frequency (RF)-enabled blood pressure device PLEASANTON, Calif. , April 22, 2025 /PRNewswire/ -- Movano Health (Nasdaq: MOVE), a pioneer in health technology, today announced positive results of its most recent 81-participant blood pressure clinical study.
Movano Health's Proprietary Cuffless Blood Pressure Device Once Again Achieves Accuracy Commensurate with the FDA's Requirements
Neutral
PRNewsWire
3 months ago
Movano's Evie Ring Adds New Personalization and Trend Tracking to Support Women's Wellness Journey
Upgrades Also Include Integration with Apple Health, Manual Post-Workout Logging PLEASANTON, Calif. , March 10, 2025 /PRNewswire/ -- Movano Health (Nasdaq: MOVE), a pioneer in health technology and maker of the Evie Ring, today announced a series of new data personalization, trend tracking and integration features on the ring's companion app that expand support for women's wellness journeys.
Movano's Evie Ring Adds New Personalization and Trend Tracking to Support Women's Wellness Journey
Neutral
PRNewsWire
4 months ago
Movano Health Commences Clinical Study with New Cuffless Blood Pressure Device
New proprietary RF hardware delivers significantly enhanced signal fidelity PLEASANTON, Calif. , Feb. 4, 2025 /PRNewswire/ -- Movano Health (Nasdaq: MOVE) announced today that it has commenced a blood pressure clinical trial with its newly developed cuffless blood pressure wrist wearable.
Movano Health Commences Clinical Study with New Cuffless Blood Pressure Device
Neutral
PRNewsWire
5 months ago
Movano Health Launches EvieAI Virtual Wellness Assistant
Newest Evie Ring feature is the first medical journal trained AI companion in a wearable PLEASANTON, Calif. , Jan. 8, 2025 /PRNewswire/ -- Movano Health  (Nasdaq:  MOVE ) today announced the latest enhancement to its Evie smart ring for women with the beta release of EvieAI, the first wearable-based virtual wellness assistant trained exclusively with data from medical journals.
Movano Health Launches EvieAI Virtual Wellness Assistant
Neutral
PRNewsWire
5 months ago
Movano Health Welcomes Dr. Shaheen Wirk to its Board of Directors
PLEASANTON, Calif. , Jan. 2, 2025 /PRNewswire/ -- Movano Health (Nasdaq: MOVE), a pioneer in health technology, today announced the expansion of its board of directors with the addition of Dr. Shaheen Wirk, a leader in healthcare dedicated investment with a track record of success in medicine, partnerships, and research.
Movano Health Welcomes Dr. Shaheen Wirk to its Board of Directors
Neutral
PRNewsWire
6 months ago
Movano Health Receives FDA Clearance for EvieMED Ring
Company's first 510(k) clearance unlocks a TAM of $40 billion in healthcare B2B opportunities PLEASANTON, Calif. , Dec. 2, 2024 /PRNewswire/ -- Movano Health  (Nasdaq: MOVE), a pioneer in health technology, today announced U.S. Food and Drug Administration (FDA) 510(k) clearance for the pulse oximeter in its EvieMED Ring.
Movano Health Receives FDA Clearance for EvieMED Ring
Neutral
Seeking Alpha
7 months ago
Movano Inc. (MOVE) Q3 2024 Earnings Call Transcript
Movano Inc. (NASDAQ:MOVE ) Q3 2024 Earnings Conference Call November 14, 2024 5:00 PM ET Company Participants J. Cogan - CFO John Mastrototaro - CEO Tyla Bucher - Chief Marketing Officer Michael Soule - Chief Commercial Officer Conference Call Participants Bruce Jackson - The Benchmark Company Operator Ladies and gentlemen, greetings, and welcome to the Movano Health Third Quarter Earnings Conference Call.
Movano Inc. (MOVE) Q3 2024 Earnings Call Transcript
Neutral
PRNewsWire
7 months ago
Movano Health Reports Q3 2024 Financial Results and Provides Business Update
Highlights successful Evie Ring back-in-stock execution Updates status of EvieMED 510(k) application review Focuses on launch of EvieMED and securing B2B opportunities Conference Call at 2:00 PM PT/ 5:00 PM ET Today PLEASANTON, Calif. , Nov. 14, 2024 /PRNewswire/ -- Movano Health (Nasdaq: MOVE), a pioneer in health technology, reported third quarter 2024 results and provided a business update.
Movano Health Reports Q3 2024 Financial Results and Provides Business Update
Charts implemented using Lightweight Charts™